In the context of CRC, we demonstrated that hydrogel scaffolds implanted directly at the tumor site could sustainably inhibit EGFR internalization, increase cetuximab binding to tumor cells, and enhance cetuximab‐mediated ADCC activity. The gene discussed is EGFR; the disease is colorectal carcinoma.